patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_848609 | REC_0002201 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.3 | 55 | female | 1 | 15 | 3.9 | 4 | sotorasib 960 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:57.387471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520681 | REC_0002202 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.4 | 78 | male | 2 | 18 | 5.9 | 3 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:57.387706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112953 | REC_0002203 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 11 | 16.8 | 65 | male | 0 | 10 | 3.2 | 2 | alectinib 600 mg BID | 15.7 | false | MSI-H | 2026-03-15T05:35:57.387941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318331 | REC_0002204 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 8 | 67 | female | 0 | 44 | 4.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.4 | false | MSS | 2026-03-15T05:35:57.388227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730258 | REC_0002205 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 34 | 9.3 | 61 | male | 1 | 18 | 6.2 | 1 | entrectinib 600 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:57.388470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368098 | REC_0002206 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 16 | 77 | female | 1 | 13 | 4.5 | 1 | sotorasib 960 mg daily | 16.1 | true | MSI-H | 2026-03-15T05:35:57.388703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635728 | REC_0002207 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 15.2 | 76 | female | 0 | 26 | 5.6 | 6 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:57.388939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850455 | REC_0002208 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 16.4 | 65 | male | 1 | 9 | 4.8 | 3 | entrectinib 600 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:57.389173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433678 | REC_0002209 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 9.1 | 75 | female | 1 | 8 | 7.4 | 2 | alectinib 600 mg BID | 15.5 | true | MSS | 2026-03-15T05:35:57.389405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304492 | REC_0002210 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 34 | 9.5 | 75 | female | 0 | 19 | 5.5 | 2 | entrectinib 600 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:57.389637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640534 | REC_0002211 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 4.3 | 68 | male | 1 | 14 | 5.3 | 6 | sotorasib 960 mg daily | 7.3 | false | MSS | 2026-03-15T05:35:57.389920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157343 | REC_0002212 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 9 | 54 | female | 0 | 24 | 4.9 | 6 | alectinib 600 mg BID | 9.3 | false | MSS | 2026-03-15T05:35:57.390156+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992182 | REC_0002213 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 16 | 7.2 | 74 | female | 2 | 13 | 4.2 | 2 | pembrolizumab 200 mg q3w | 25.5 | false | MSS | 2026-03-15T05:35:57.390384+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649608 | REC_0002214 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 17.2 | 55 | female | 1 | 13 | 7.3 | 5 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:35:57.390621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563574 | REC_0002215 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.8 | 68 | male | 1 | 61 | 6.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 7 | false | MSS | 2026-03-15T05:35:57.390853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413825 | REC_0002216 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.6 | 62 | male | 0 | 24 | 5.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 10 | true | MSS | 2026-03-15T05:35:57.391084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889562 | REC_0002217 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.8 | 76 | female | 1 | 20 | 4.4 | 4 | alectinib 600 mg BID | 10.3 | true | MSI-H | 2026-03-15T05:35:57.391313+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456635 | REC_0002218 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 20.7 | 73 | female | 1 | 8 | 7.1 | 2 | sotorasib 960 mg daily | 16.5 | true | MSS | 2026-03-15T05:35:57.391543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772564 | REC_0002219 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.4 | 76 | female | 1 | 14 | 6 | 7 | osimertinib 80 mg daily | 16.1 | false | MSS | 2026-03-15T05:35:57.391775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634525 | REC_0002220 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 3.5 | 69 | female | 1 | 32 | 7.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.3 | false | MSS | 2026-03-15T05:35:57.392001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720875 | REC_0002221 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 14.3 | 66 | female | 0 | 14 | 6.1 | 1 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:57.392276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343524 | REC_0002222 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 15.2 | 58 | female | 1 | 15 | 5.7 | 5 | entrectinib 600 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:57.392516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928602 | REC_0002223 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 15.7 | 68 | female | 0 | 22 | 6.3 | 5 | sotorasib 960 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:57.392754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362723 | REC_0002224 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.8 | 62 | male | 1 | 61 | 5.5 | 8 | carboplatin + paclitaxel + pembrolizumab | 7.3 | false | MSS | 2026-03-15T05:35:57.393043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162757 | REC_0002225 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 12.8 | 55 | female | 1 | 31 | 4.5 | 2 | alectinib 600 mg BID | 16.6 | true | MSS | 2026-03-15T05:35:57.393287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529152 | REC_0002226 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 12.7 | 64 | female | 0 | 15 | 3.7 | 2 | sotorasib 960 mg daily | 25.1 | true | MSI-H | 2026-03-15T05:35:57.393524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153935 | REC_0002227 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 18.4 | 65 | male | 0 | 12 | 5.5 | 5 | alectinib 600 mg BID | 12.4 | true | MSI-H | 2026-03-15T05:35:57.393763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558302 | REC_0002228 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.5 | 75 | female | 2 | 23 | 4.4 | 4 | osimertinib 80 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:57.393996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513689 | REC_0002229 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 7.5 | 70 | female | 3 | 3 | 7.7 | 9 | sotorasib 960 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:57.394228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589722 | REC_0002230 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 5 | 70 | female | 0 | 56 | 5.5 | 2 | pembrolizumab 200 mg q3w | 25.8 | false | MSS | 2026-03-15T05:35:57.394456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438468 | REC_0002231 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 8.8 | 69 | female | 1 | 51 | 5.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 16.9 | false | MSS | 2026-03-15T05:35:57.394686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421029 | REC_0002232 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 6.5 | 60 | male | 1 | 13 | 4.8 | 3 | pembrolizumab 200 mg q3w | 15.2 | true | MSS | 2026-03-15T05:35:57.394925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371682 | REC_0002233 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 12.7 | 68 | female | 1 | 5 | 5.7 | 4 | alectinib 600 mg BID | 11.8 | true | MSI-H | 2026-03-15T05:35:57.395165+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412169 | REC_0002234 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 9 | 78 | female | 2 | 10 | 6 | 1 | osimertinib 80 mg daily | 20.5 | false | MSS | 2026-03-15T05:35:57.395398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165024 | REC_0002235 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 17.7 | 71 | female | 2 | 14 | 4.3 | 4 | pembrolizumab 200 mg q3w | 10 | false | MSI-H | 2026-03-15T05:35:57.395628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301635 | REC_0002236 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 17.1 | 76 | male | 1 | 15 | 6.1 | 1 | osimertinib 80 mg daily | 14.7 | true | MSS | 2026-03-15T05:35:57.395871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105330 | REC_0002237 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 8.3 | 48 | male | 0 | 11 | 5 | 7 | osimertinib 80 mg daily | 8.4 | false | MSS | 2026-03-15T05:35:57.396216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843902 | REC_0002238 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 10.4 | 72 | female | 1 | 21 | 6.6 | 2 | sotorasib 960 mg daily | 14.7 | true | MSS | 2026-03-15T05:35:57.396462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340774 | REC_0002239 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 2.1 | 55 | male | 1 | 4 | 5.2 | 2 | pembrolizumab 200 mg q3w | 21.2 | true | MSS | 2026-03-15T05:35:57.396699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783626 | REC_0002240 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 4.9 | 52 | male | 0 | 44 | 5 | 1 | pembrolizumab 200 mg q3w | 28.4 | false | MSS | 2026-03-15T05:35:57.396935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293094 | REC_0002241 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 26 | 9.6 | 67 | female | 0 | 18 | 5.3 | 0 | entrectinib 600 mg daily | 31.4 | false | MSS | 2026-03-15T05:35:57.397171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902936 | REC_0002242 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 8.6 | 64 | male | 1 | 36 | 6.2 | 5 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:35:57.397403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213893 | REC_0002243 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 16.2 | 68 | female | 1 | 8 | 5.8 | 9 | sotorasib 960 mg daily | 8.2 | false | MSI-H | 2026-03-15T05:35:57.397636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960569 | REC_0002244 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.7 | 72 | female | 1 | 17 | 6.7 | 5 | osimertinib 80 mg daily | 15.5 | true | MSI-H | 2026-03-15T05:35:57.397868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_727990 | REC_0002245 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 8.6 | 69 | female | 0 | 8 | 4.1 | 1 | entrectinib 600 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:57.398096+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872875 | REC_0002246 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 9.2 | 65 | male | 1 | 43 | 7.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.8 | false | MSS | 2026-03-15T05:35:57.398330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106797 | REC_0002247 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 22.1 | 58 | male | 0 | 24 | 6.4 | 4 | entrectinib 600 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:57.398566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331447 | REC_0002248 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 13.9 | 49 | male | 0 | 18 | 4.8 | 7 | alectinib 600 mg BID | 7.1 | false | MSS | 2026-03-15T05:35:57.398807+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698399 | REC_0002249 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.7 | 63 | male | 1 | 15 | 4.6 | 5 | alectinib 600 mg BID | 12.5 | true | MSS | 2026-03-15T05:35:57.399060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774327 | REC_0002250 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6 | 66 | female | 1 | 68 | 4.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 29.5 | false | MSS | 2026-03-15T05:35:57.399416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650375 | REC_0002251 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.7 | 71 | female | 2 | 10 | 5.1 | 7 | osimertinib 80 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:57.399695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503733 | REC_0002252 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 15 | 5.7 | 81 | female | 2 | 74 | 7.1 | 0 | pembrolizumab 200 mg q3w | 25.7 | true | MSS | 2026-03-15T05:35:57.399932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637678 | REC_0002253 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 14.4 | 63 | male | 0 | 10 | 7.5 | 1 | sotorasib 960 mg daily | 18.3 | true | MSI-H | 2026-03-15T05:35:57.400317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628457 | REC_0002254 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7 | 55 | female | 0 | 56 | 6.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:35:57.400576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660626 | REC_0002255 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 11.9 | 76 | female | 2 | 15 | 4.2 | 2 | osimertinib 80 mg daily | 24 | true | MSS | 2026-03-15T05:35:57.400825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221471 | REC_0002256 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 9.2 | 76 | female | 2 | 22 | 6 | 0 | alectinib 600 mg BID | 20.9 | false | MSS | 2026-03-15T05:35:57.401059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484467 | REC_0002257 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 12.6 | 57 | male | 0 | 19 | 7.2 | 4 | sotorasib 960 mg daily | 18.6 | false | MSS | 2026-03-15T05:35:57.401302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247797 | REC_0002258 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 15.4 | 69 | female | 1 | 8 | 6.4 | 1 | entrectinib 600 mg daily | 17 | false | MSS | 2026-03-15T05:35:57.401537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274834 | REC_0002259 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 13.5 | 67 | female | 1 | 18 | 5.6 | 5 | sotorasib 960 mg daily | 8.4 | true | MSI-H | 2026-03-15T05:35:57.401778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988813 | REC_0002260 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 9.5 | 72 | female | 1 | 23 | 4.2 | 6 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:57.402010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397126 | REC_0002261 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.2 | 71 | female | 2 | 16 | 5.9 | 1 | osimertinib 80 mg daily | 18.2 | true | MSS | 2026-03-15T05:35:57.402250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930540 | REC_0002262 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 14.3 | 78 | female | 0 | 11 | 4.5 | 2 | entrectinib 600 mg daily | 6 | true | MSS | 2026-03-15T05:35:57.402486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533798 | REC_0002263 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 8.6 | 51 | female | 0 | 23 | 6.3 | 4 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:57.402819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392833 | REC_0002264 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 4.8 | 53 | female | 0 | 9 | 5.6 | 4 | osimertinib 80 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:57.403060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651764 | REC_0002265 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 5.4 | 79 | female | 3 | 38 | 5.2 | 7 | pembrolizumab 200 mg q3w | 10.8 | false | MSS | 2026-03-15T05:35:57.403289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201233 | REC_0002266 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 6.5 | 62 | female | 0 | 17 | 5.9 | 2 | entrectinib 600 mg daily | 4.8 | true | MSS | 2026-03-15T05:35:57.403526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570643 | REC_0002267 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 7.2 | 80 | female | 3 | 12 | 5.4 | 5 | entrectinib 600 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:57.403755+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_251651 | REC_0002268 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 12.2 | 67 | female | 0 | 15 | 5.9 | 1 | pembrolizumab 200 mg q3w | 19 | false | MSI-H | 2026-03-15T05:35:57.403991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_479897 | REC_0002269 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 12.7 | 69 | female | 1 | 15 | 3.8 | 2 | alectinib 600 mg BID | 21.1 | true | MSS | 2026-03-15T05:35:57.404281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340555 | REC_0002270 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 9.6 | 60 | male | 1 | 13 | 7 | 6 | alectinib 600 mg BID | 14.8 | false | MSS | 2026-03-15T05:35:57.404522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547707 | REC_0002271 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.2 | 84 | female | 2 | 16 | 6 | 8 | entrectinib 600 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:57.404766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376105 | REC_0002272 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.7 | 76 | female | 2 | 34 | 7.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:35:57.404998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152499 | REC_0002273 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 17.8 | 60 | male | 1 | 16 | 7.5 | 4 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:57.405242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831561 | REC_0002274 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13.1 | 66 | female | 0 | 13 | 5.5 | 6 | alectinib 600 mg BID | 11.6 | false | MSI-H | 2026-03-15T05:35:57.405482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116887 | REC_0002275 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 8.4 | 69 | female | 0 | 19 | 4.1 | 10 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:57.405710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600672 | REC_0002276 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 12.7 | 74 | female | 3 | 3 | 5.6 | 8 | osimertinib 80 mg daily | 14.2 | true | MSI-H | 2026-03-15T05:35:57.406017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194633 | REC_0002277 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 6.4 | 63 | male | 0 | 8 | 5.2 | 1 | alectinib 600 mg BID | 25 | false | MSS | 2026-03-15T05:35:57.406255+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485263 | REC_0002278 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 7.8 | 83 | female | 2 | 0 | 5.8 | 5 | entrectinib 600 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:57.406484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544621 | REC_0002279 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 21.8 | 61 | male | 1 | 9 | 6.1 | 5 | osimertinib 80 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:57.406721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756398 | REC_0002280 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.5 | 68 | male | 1 | 70 | 6.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:35:57.406956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222726 | REC_0002281 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 9.5 | 64 | male | 2 | 19 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.9 | true | MSS | 2026-03-15T05:35:57.407193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428929 | REC_0002282 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 15 | 69 | female | 0 | 7 | 5.6 | 5 | pembrolizumab 200 mg q3w | 9.8 | true | MSI-H | 2026-03-15T05:35:57.407434+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412867 | REC_0002283 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 17.6 | 66 | male | 1 | 15 | 6 | 6 | sotorasib 960 mg daily | 5.7 | false | MSI-H | 2026-03-15T05:35:57.407669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712682 | REC_0002284 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 10.7 | 70 | female | 1 | 7 | 3.9 | 4 | sotorasib 960 mg daily | 6.8 | true | MSI-H | 2026-03-15T05:35:57.407904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768992 | REC_0002285 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 8.1 | 72 | female | 2 | 73 | 6.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.8 | true | MSS | 2026-03-15T05:35:57.408182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242557 | REC_0002286 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 5 | 61 | female | 1 | 16 | 6.6 | 5 | pembrolizumab 200 mg q3w | 7.2 | true | MSS | 2026-03-15T05:35:57.408425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881163 | REC_0002287 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 9.2 | 64 | male | 0 | 20 | 7.8 | 6 | osimertinib 80 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:57.408660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590057 | REC_0002288 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 5.3 | 67 | female | 0 | 18 | 6.2 | 1 | osimertinib 80 mg daily | 26.4 | false | MSS | 2026-03-15T05:35:57.408891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771973 | REC_0002289 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 14.2 | 71 | female | 1 | 14 | 5.6 | 6 | osimertinib 80 mg daily | 14.8 | true | MSI-H | 2026-03-15T05:35:57.409210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518745 | REC_0002290 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 12.8 | 88 | female | 2 | 13 | 5.2 | 1 | alectinib 600 mg BID | 23.2 | false | MSI-H | 2026-03-15T05:35:57.409505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807536 | REC_0002291 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 8.7 | 72 | male | 2 | 16 | 6.3 | 7 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:35:57.409772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875943 | REC_0002292 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 15.8 | 54 | male | 0 | 15 | 5 | 4 | alectinib 600 mg BID | 14.7 | false | MSI-H | 2026-03-15T05:35:57.410018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329955 | REC_0002293 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 15.2 | 67 | female | 0 | 24 | 6 | 3 | pembrolizumab 200 mg q3w | 11.8 | false | MSS | 2026-03-15T05:35:57.410253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850584 | REC_0002294 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.2 | 69 | female | 0 | 13 | 7 | 6 | alectinib 600 mg BID | 9.8 | true | MSS | 2026-03-15T05:35:57.410486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386452 | REC_0002295 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 15 | 85 | female | 1 | 15 | 3.4 | 1 | osimertinib 80 mg daily | 18.6 | false | MSS | 2026-03-15T05:35:57.410718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196734 | REC_0002296 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 11 | 15.7 | 67 | female | 1 | 10 | 7.3 | 4 | osimertinib 80 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:35:57.410950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504976 | REC_0002297 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 8.4 | 67 | female | 1 | 22 | 4.5 | 2 | osimertinib 80 mg daily | 16.9 | true | MSS | 2026-03-15T05:35:57.411179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257714 | REC_0002298 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 13.7 | 68 | female | 1 | 18 | 6.3 | 5 | pembrolizumab 200 mg q3w | 11.6 | true | MSS | 2026-03-15T05:35:57.411420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888376 | REC_0002299 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 7.1 | 69 | female | 1 | 26 | 6.2 | 8 | sotorasib 960 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:57.411649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293418 | REC_0002300 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5.4 | 74 | female | 1 | 45 | 6.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.5 | false | MSS | 2026-03-15T05:35:57.411881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.